Not Yet RecruitingPhase 1

A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)

400 participantsStarted 2026-09-15

Plain-language summary

The purpose of this trial is to compare what happens to MK-1406 in the body of healthy participants when it is given as 2-injections and 3-injections. Researchers also want to learn about the safety of MK-1406 and if people tolerate it.

Who can participate

Age range

18 Years – 64 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health * Has body mass index (BMI) 18.0 to 32.0 kg/m\^2 Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * History of clinically significant endocrine, Gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases * History of cancer (malignancy)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Part 1: Area Under the Concentration Time Curve From Time 0 to 4 Weeks (AUC0-4w) of MK-1406

Timeframe: Predose and at designated timepoints up to 4 weeks postdose

Part 1 and Part 2: Number of Participants Who Experience One or More Adverse Events (AEs)

Timeframe: Up to approximately 43 days postdose

Part 1 and Part 2: Number of Participants Who Experience At Least One Solicited Injection-Site Reaction

Timeframe: Up to approximately 7 days postdose

Part 1 and Part 2: Number of Participants Who Discontinue Study Due to an AE

Timeframe: Up to approximately 43 days postdose

Trial details

NCT IDNCT07743151

SponsorMerck Sharp & Dohme LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-02-05

View on ClinicalTrials.gov More Healthy trials

Who can participate

Age range

18 Years – 64 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Part 1: Area Under the Concentration Time Curve From Time 0 to 4 Weeks (AUC0-4w) of MK-1406

Timeframe: Predose and at designated timepoints up to 4 weeks postdose

Part 1 and Part 2: Number of Participants Who Experience One or More Adverse Events (AEs)

Timeframe: Up to approximately 43 days postdose

Part 1 and Part 2: Number of Participants Who Experience At Least One Solicited Injection-Site Reaction

Timeframe: Up to approximately 7 days postdose

Part 1 and Part 2: Number of Participants Who Discontinue Study Due to an AE

Timeframe: Up to approximately 43 days postdose